An analysis of ctDNA testing for early detection of recurrence showed that test had high sensitivity across multiple sites of ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

Pfizer Inc (NYSE:PFE) shares are trading higher Monday. Some of the optimism may be surrounding activist Starboard Value's ...

Following a tough opening salvo from Starboard Value last fall, Pfizer is getting a chance to catch its breath in the ...

Pfizer Inc. got a reprieve — at least for now — in its battle with activist investor Starboard Value LP, according to people ...

Biohaven, acquired by Pfizer in 2022, allegedly took doctors to high-end restaurants and paid speaker honoraria for ...

Over the years, the U.S. Department of Justice (DOJ) has taken a host of drugmakers to task over alleged kickback payments ...

Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe ...

Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.